Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  05/18 11:30:16 am EDT
321.25 CHF   -0.34%
04:08aJudgement On The First Drug Patent Linkage Lawsuit In China Is Issued
AQ
05/17AlphaValue/Baader Europe Lifts Price Target on Roche, Maintains Add Recommendation
MT
05/16TRANSCRIPT : Roche Holding AG - Special Call
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ROCHE HOLDINGS AG : Deutsche Bank keeps its Buy rating

01/26/2022 | 06:10am EDT
share with twitter
share with LinkedIn
share with facebook

Already positive, the research from Deutsche Bank and its analyst Emmanuel Papadakis still consider the stock as a Buy opportunity. The target price is unchanged at CHF 425.


© MarketScreener with dpa-AFX Analyser 2022
All news about ROCHE HOLDING AG
04:08aJudgement On The First Drug Patent Linkage Lawsuit In China Is Issued
AQ
05/17AlphaValue/Baader Europe Lifts Price Target on Roche, Maintains Add Recommendation
MT
05/16TRANSCRIPT : Roche Holding AG - Special Call
CI
05/13PUMP / DUMP #31 : The week's gainers and losers
05/13ROCHE HOLDINGS AG : Reduced to Neutral by Jefferies
MD
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/12ROCHE HOLDINGS AG : Gets a Neutral rating from Morgan Stanley
MD
05/12ROCHE HOLDINGS AG : Deutsche Bank lowers his opinion and switches to Neutral
MD
05/12Roche Teams Up With Global Fund To Boost Diagnostic Systems In Low, Middle-income Natio..
MT
05/12Roche enters partnership with the Global Fund to support low- and middle-income countri..
GL
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 64 123 M 64 891 M 64 891 M
Net income 2022 14 877 M 15 055 M 15 055 M
Net Debt 2022 10 808 M 10 937 M 10 937 M
P/E ratio 2022 17,3x
Yield 2022 3,02%
Capitalization 261 B 264 B 264 B
EV / Sales 2022 4,24x
EV / Sales 2023 4,07x
Nbr of Employees 100 920
Free-Float 82,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 321,25 CHF
Average target price 394,40 CHF
Spread / Average Target 22,8%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-14.97%263 868
JOHNSON & JOHNSON2.59%470 547
PFIZER, INC.-14.65%288 063
ABBVIE INC.12.58%273 513
ELI LILLY AND COMPANY6.87%271 308
NOVO NORDISK A/S1.88%240 809